



FROM FARMER TO PHARMA  
**Company Presentation**

---

May 2018



# Forward Looking Statement

This presentation was prepared as a summary and for convenience only and does not intend to substitute the need to peruse the reports the company publishes for the public.

Full and comprehensive information in connection with the company and its business can be found in the periodic and immediate reports published by the company on the Securities website at [www.magna.isa.gov.il](http://www.magna.isa.gov.il). Similarly the predictions are based on data, information and estimations known by the company on the date this presentation was prepared, and the company does not undertake to revise and/or change such predictions and/or estimations to reflect events and/or circumstances to apply after the presentation was prepared.

---

This presentation may include data and information not included in the company's periodic and/or immediate reports as published to the public or the manner they are presented within the framework of this presentation is different than the manner included in the reports published by the company to the public. In the event of a conflict between the reports published to the public and the data in this presentation, only refer to the data published by the company in the reports the company publishes to the public by virtue of statutory requirements.

In this presentation, the company included forward looking information as defined in the Securities Law, 5728 - 1968 in relation to itself and in relation to held or affiliated companies. Such information includes, *inter alia*, predictions, objectives, estimations, evaluations and other information relating to future events or affairs, whereby the realization thereof is uncertain and may be affected by factors that cannot be evaluated in advance and which are not in the company's control. Including but not limited to technological and engineering difficulties, **climate disasters, natural disasters and insects**, regulatory changes, difficulties or delays in connection with research grants, scope of future funding resources and ability to actually raise these resources, changes in work plans, not receiving the relevant health authorities approvals on the expected date, changes in technologies, changes in target markets, the portfolio companies decisions not to continue developing the products in the format fixed to do so due to each one of the foregoing factors and/or realization of any one of the risk factors characteristic of the company's activity. Forward looking information is based on the company's management estimations, based, *inter alia* on information the company's management is aware of, on the date this presentation was prepared, including an assessment of the markets in which the company is active, statistical and public data and publications published by the various bodies and authorities, the content of which was not reviewed by the company independently and therefore the company is not responsible for the correctness thereof.

Realization of all or part of the forward looking information or in a manner that differs from what was expected or that it is not realized, will be affected, *inter alia*, by risk factors characteristic of the company's activity and from developments in the economic environment and external factors affecting the company in its fields of activity. The company has no certainty that its estimations, plans and expectations will be realized and therefore the activity results may be materially different from the estimated or implied results of this information.

# Window of Opportunities



In light of the development of the international cannabis market and alongside the opening of the regulatory gates in Israel an exceptional business opportunity manifested in the medical cannabis field Together Pharma leveraged the opportunities and within a short period of time succeeded in signing contracts to supply medical cannabis products of a scope of 78 tons annually - to Canada and to Germany

---

# The International Opportunity



Grand view research

The international medical cannabis market

**is estimated at approximately 55 Billion Dollars annually in 2020**

---


According to estimations, the medical cannabis market is expected **to grow considerably** during the course of the coming years

# The International Opportunity

The medical cannabis  
**Is legitimized in more and more countries around the world**

Medical Studies  
**Prove the effectiveness in a broad range of fields**

| Anorexia | Alzheimer | Cancer  
| Autism | Multiple Sclerosis | Attention Deficit Disorders



Grand view research

# The Opportunity in Israel

## Regulatory reform in the medical cannabis field

The State of Israel opened the regulatory dam and allows four business licenses, all of which are held by Together Pharma. The company's holding of the four business licenses enabling the company full control over the value chain and independence of third party entities. The company is in the advanced stages of establishing a farm in the south of the country



### **License to increase quantity of medical cannabis**

Licenses to operate, design, establish and adapt greenhouses to increase quantity of medical cannabis



### **License to establish and operate growing farm**

Licenses to operate, design and establish greenhouses to grow cannabis plants, The company is in the advanced stages of establishing a farm in the south of the country



### **License to establish and operate manufacturing plant**

Licenses to act to design and establish a production enterprise for medical cannabis products the company is at the design stages of a pharmaceutical enterprise of GMP Standard



### **Emporium License**

Licenses to operate, design and establish emporiums to market and distribute medical cannabis



# The Opportunity in Israel

# Optimal climate conditions to grow medical cannabis



## Fitting humidity percentages

Safeguarding the plant from insects and enabling optimal growth



## Optimal temperature

Saving energy in the winter and in the summer, and thereby saving considerable production costs



## Approximately 300 days sun, a year on average

Optimal light saving on production costs, and therefore the plan is less exposed to insects



## High UV rays

Vital for effective growth of cannabis

- **Conditions allowing for low production costs**, to date estimated at approximately one quarter of the cost of growing in cold countries such as Canada or Europe
- **Multiple growing cycles of the cannabis plant** and reaching excess production per land cell over other countries

# Together Pharma's Opportunity

78

The company has sales agreements in Canada and in Germany of a total scope of approximately 78 tons a year

---

34

The company is in the establishment stages of a greenhouse site in the south of the country with the ability to produce approximately 34 tons annually

---

30

The company signed a partnership agreement to grow and produce medical cannabis products in Africa of a minimum scope of approximately 30 dunam


---

4

The company holds four business licenses in Israel and is advancing the establishment of a greenhouse in the south

---





THCV



**Business Card**





### **Nissim Bracha**

**Director and controlling shareholder in Together Pharma.**

CEO and Chairman of the Board of Directors in Together Pharma

---

Dozens of years experience in the agricultural sector, today owners of several real estate properties companies



### **Nir Sosinsky**

**Director and controlling shareholder in Together Pharma.**

Co-CEO in Globus Pharma (the activity company)

---

Co-owners and CEO of "Adam Amit Management and Engineering". Having a wealth of experience in working with bureaucratic systems and establishing complex engineering systems



### **Guy Atia**

**Director and controlling shareholder in Together Pharma.**

Co-CEO in Globus Pharma (the activity company)

---

Owner of the R.H.S. Security Company  
Expert in the security field, security consultant to leading companies in Israel and in the municipal sector

**55**  
**Accumulative years of experience in entrepreneurship and management**

Translated into a commitment to creating a large and significant company with vast international activity in the medical cannabis field. The controlling shareholders have the financial robustness to fund the company's activity

# Professional Team

Hovav  
Amram

**Company  
Engineer and  
Production Sites  
Manager**

Itay

**Master  
Grower**

In charge of the growing and agronomy field in the company. A wealth of international experience in the field

Uri Ben Or

**Vice President  
Finance**

(Retired) Brigadier General  
Meir Ben Yishai

**Defense and Security  
Consultant**

Accompanying Law Firm Weinstock/ Zahavi  
**The company's Legal counsel in the regulatory field**

Accompanying Law Firm Pearl/ Cohen/ Zedek/ Baratz  
**The company's Legal counsel commercial and capital market field**



# The Vision |

**To manufacture and distribute worldwide  
quality medical cannabis products**



# Our uniqueness

The company holds the four possible licenses issued by the State of Israel



Control over the entire production chain



Wealth of experience in project management and entrepreneurial drive




Two production centers in Israel and in an additional country

Multi field managerial experience in various entrepreneurs, agriculture, engineering, security and real estate properties

The company's international ties and its grasp on an additional production center outside Israel provide the company the flexibility and independence of the Israeli regulations

# Control over each value chain

The Together Pharma company complies with all of the MCU's (Medical Cannabis Unit at the Ministry of Health) stringent requirements the company has licenses for the entire value chain enabling the company to have business flexibility.





# Production of a broad variety of medical cannabis products



## Creams

CBD enriched creams designed to treat various skin diseases such as psoriasis



## Capsules

Allows for oral consumption in a measured and controlled form



## Oils

For oral consumption with no need to smoke the product, also suitable for children and non-smoking populations



## Ready Cigarettes

Single cigarettes of suitable weight for one time use allowing for immediate consumption in the form of smoking



## Inflorescence

For use as a product to be consumed in the form of smoking whether a self-rolling cigarette or other smoking means



# Current Status

The company signed sale agreements of a scope of 78 tons annually and the company began building two growing sites, both in Israel and in Africa. The Company signed a memorandum of understanding for cooperation with a Premier company to manufacture cosmetic products based on minerals from the Dead Sea enriched with the CBD component.

The Company is examining the option of establishing an additional production site in Europe to produce and distribute medical cannabis based products Together Pharma intends on already marketing medical cannabis products in the first quarter of 2019



Establishing enterprise for the  
production of standardized  
medical cannabis products  
GMP



Immediate Export  
approval from  
African Country

**7.5  
Acres**

Greenhouses under  
construction  
in Africa



**5  
Acres**

Greenhouses under  
construction  
in Israel

**78  
Tons**

Annual Sales  
Potential  
To date

# Milestones



## Value Creation Events

# Brighter Future

A silhouette of a person with long hair, sitting on a rock and looking out at a sunset over the ocean. The person is facing right, and the sun is low on the horizon, creating a warm, golden glow across the sky and water. The person's hair is long and dark, and they are wearing a dark top. The rock they are sitting on is dark and textured. The ocean is visible in the foreground, and the horizon line is clearly defined.

For the company to have a global sales and marketing basis

Developing a broad variety of cannabis plant based products

collaborations in the research and development field with universities and leading research institutions worldwide

# The Business Model

1

Annual scope of supply in Germany  
(pursuant to) a signed agreement:  
25 tons

Annual scope of supply in Canada  
(pursuant to signed contracts):  
53 tons

2

Foreseeable Production  
expenses per gram:  
less than -2 dollar per gram  
(growing and processing at  
GMP enterprise)

3

Total expected estimated  
annual revenues pursuant to  
existing agreements  
Exceeding 350 million  
dollars annual

# In conclusion



The controlling shareholders have the financial robustness to fund the company's activity

Business Partners: Yamko-Yadpaz, Dead Sea Premier, Panaxia, clients from Germany & Canada

Expected production cost per gram less than two gram

Activity in medical cannabis niches such as: inflorescence, creams and preparations, smoking products and reviewing accessing additional niches

2 production sites under construction, in Israel and in Africa enabling production of medical cannabis of large scopes and low costs

Together Pharma holds all the licenses required in Israel to grow medical cannabis

Expected to start medical cannabis consumption marketing - First Quarter of 2019

Distribution agreements in Germany and Canada of a total scope of 78 tons





# FROM FARMER TO PHARMA

---

May 2018

